EG25994A - Biaryl substituted triazoles as sodium channel blockers - Google Patents

Biaryl substituted triazoles as sodium channel blockers

Info

Publication number
EG25994A
EG25994A EGNA2005000548A EG25994A EG 25994 A EG25994 A EG 25994A EG NA2005000548 A EGNA2005000548 A EG NA2005000548A EG 25994 A EG25994 A EG 25994A
Authority
EG
Egypt
Prior art keywords
sodium channel
channel blockers
substituted triazoles
biaryl substituted
biaryl
Prior art date
Application number
Other languages
English (en)
Inventor
Prasun K Chakravarty
Michael H Fisher
Brenda Palucki
Min K Park
William H Parsons
Bishan Zhou
James P Carey
Douglas E Frantz
Michael H Kress
Damian Weaver
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of EG25994A publication Critical patent/EG25994A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EGNA2005000548 2003-03-18 2005-09-18 Biaryl substituted triazoles as sodium channel blockers EG25994A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45595203P 2003-03-18 2003-03-18
PCT/US2004/007830 WO2004083190A1 (en) 2003-03-18 2004-03-12 Biaryl substituted triazoles as sodium channel blockers

Publications (1)

Publication Number Publication Date
EG25994A true EG25994A (en) 2012-11-28

Family

ID=33030073

Family Applications (1)

Application Number Title Priority Date Filing Date
EGNA2005000548 EG25994A (en) 2003-03-18 2005-09-18 Biaryl substituted triazoles as sodium channel blockers

Country Status (34)

Country Link
US (2) US7326726B2 (is)
EP (1) EP1606269B1 (is)
JP (1) JP4482554B2 (is)
KR (1) KR100737721B1 (is)
CN (2) CN1788002A (is)
AR (1) AR044503A1 (is)
AT (1) ATE412639T1 (is)
AU (1) AU2004221885C1 (is)
BR (1) BRPI0408407A (is)
CA (1) CA2519252C (is)
CL (1) CL2004000551A1 (is)
CY (1) CY1108720T1 (is)
DE (1) DE602004017438D1 (is)
DK (1) DK1606269T3 (is)
EC (1) ECSP056018A (is)
EG (1) EG25994A (is)
ES (1) ES2314387T3 (is)
HR (1) HRP20050816A2 (is)
IS (1) IS8001A (is)
JO (1) JO2480B1 (is)
MA (1) MA27665A1 (is)
MX (1) MXPA05009847A (is)
MY (1) MY142651A (is)
NO (1) NO20054775L (is)
NZ (1) NZ542205A (is)
PE (1) PE20041066A1 (is)
PL (1) PL1606269T3 (is)
PT (1) PT1606269E (is)
RU (1) RU2356897C2 (is)
SI (1) SI1606269T1 (is)
TW (1) TWI337605B (is)
UA (1) UA81660C2 (is)
WO (2) WO2004083190A1 (is)
ZA (1) ZA200506906B (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE405840T1 (de) 2002-12-19 2008-09-15 Scripps Research Inst Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
ATE500234T1 (de) * 2003-11-10 2011-03-15 Merck Sharp & Dohme Substituierte trialzole als blocker des natriumkanals
KR20070032700A (ko) 2004-05-20 2007-03-22 폴드알엑스 파마슈티칼스, 인크. 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법
ATE472529T1 (de) 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
US8299107B2 (en) * 2007-02-08 2012-10-30 Synta Pharmaceuticals Corporation Triazole compounds that modulate HSP90 activity
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
US8952034B2 (en) 2009-07-27 2015-02-10 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (is) 2011-07-01 2018-04-28
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP6456909B2 (ja) 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
CA3076823A1 (en) 2017-10-05 2019-04-11 Biogen Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
US20210002232A1 (en) * 2018-03-09 2021-01-07 Pi Industries Ltd. Heterocyclic compounds as fungicides
CN108863965A (zh) * 2018-06-25 2018-11-23 青岛科技大学 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法
CN108794413A (zh) * 2018-06-25 2018-11-13 青岛科技大学 一种1,2,4-三氮唑-3-甲酰胺的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875782A (en) * 1907-04-29 1908-01-07 Walter H Cook Fast-nut.
TW226993B (is) * 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
JP3682075B2 (ja) * 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
IT1292091B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
CA2368631A1 (en) 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
JP2004532234A (ja) * 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
BR0312503A (pt) * 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470075B1 (ko) * 2002-11-21 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
ATE500234T1 (de) * 2003-11-10 2011-03-15 Merck Sharp & Dohme Substituierte trialzole als blocker des natriumkanals

Also Published As

Publication number Publication date
CA2519252C (en) 2008-11-18
RU2005132168A (ru) 2006-04-27
UA81660C2 (ru) 2008-01-25
PT1606269E (pt) 2008-12-16
DK1606269T3 (da) 2009-02-09
KR100737721B1 (ko) 2007-07-11
NO20054775D0 (no) 2005-10-17
ATE412639T1 (de) 2008-11-15
US20050119261A1 (en) 2005-06-02
NZ542205A (en) 2008-11-28
TWI337605B (en) 2011-02-21
JO2480B1 (en) 2009-01-20
KR20050109583A (ko) 2005-11-21
ECSP056018A (es) 2006-01-27
DE602004017438D1 (de) 2008-12-11
AU2004221885A1 (en) 2004-09-30
PE20041066A1 (es) 2005-01-22
EP1606269A1 (en) 2005-12-21
WO2004083189A1 (en) 2004-09-30
US7326726B2 (en) 2008-02-05
NO20054775L (no) 2005-12-16
MY142651A (en) 2010-12-15
CA2519252A1 (en) 2004-09-30
ES2314387T3 (es) 2009-03-16
TW200505876A (en) 2005-02-16
ZA200506906B (en) 2007-02-28
AU2004221885C1 (en) 2010-09-23
MXPA05009847A (es) 2005-12-05
CN101289428A (zh) 2008-10-22
HRP20050816A2 (hr) 2006-04-30
SI1606269T1 (sl) 2009-02-28
BRPI0408407A (pt) 2006-03-21
JP4482554B2 (ja) 2010-06-16
EP1606269B1 (en) 2008-10-29
AU2004221885B2 (en) 2010-04-22
PL1606269T3 (pl) 2009-04-30
CN1788002A (zh) 2006-06-14
JP2006520782A (ja) 2006-09-14
MA27665A1 (fr) 2005-12-01
WO2004083190A1 (en) 2004-09-30
IS8001A (is) 2005-08-29
US7572822B2 (en) 2009-08-11
CY1108720T1 (el) 2013-09-04
US20080171777A1 (en) 2008-07-17
CL2004000551A1 (es) 2005-01-21
AR044503A1 (es) 2005-09-14
RU2356897C2 (ru) 2009-05-27

Similar Documents

Publication Publication Date Title
EG25994A (en) Biaryl substituted triazoles as sodium channel blockers
DK1663235T3 (da) Beskyttede pyrazinoylguanidin-natriumkanal-blokkere
AU2003248122A8 (en) Sodium channel inhibitor
EP1542686A4 (en) ARYL-SUBSTITUTED HYDANTOIN COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS
GB0304424D0 (en) Novel compounds
EP1534259A4 (en) SULFONAMIDES AS POTASSIUM CHANNEL BLOCKING AGENTS
EP1596860A4 (en) NEW CONNECTIONS
EP1648885A4 (en) NEW CONNECTIONS
TWI319322B (en) Frozen-dried preperation containing prostaglandin
GB0302546D0 (en) Novel compounds
GB0304809D0 (en) Novel compounds
SI1485359T1 (sl) Blokatorji natrijevega kanala
GB0323098D0 (en) Improvements relating to communications
HK1088533A (en) Alaphatic pyrazinoylguanidine sodium channel blockers
GB0216212D0 (en) Sodium channel inhibitors
GB0406006D0 (en) Sodium channels
GB0406004D0 (en) Sodium channels
GB0406002D0 (en) Sodium channels
GB0406001D0 (en) Sodium channels
GB0224206D0 (en) Improvements relating to communications
GB0300484D0 (en) Novel compounds
GB0301589D0 (en) Novel compounds
GB0301591D0 (en) Novel compounds
GB0301592D0 (en) Novel compounds
GB0301593D0 (en) Novel compounds